RxDoctor Payments Data

Marie-Laurie Vanegas, PA

Physician Assistant · Miami, FLNPI 1811573827

Payments from drug & device makers

$11,007in general payments, 2019–2025

Across 390 payments — averaging $28.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Lilly USA, LLC$1K
  • Tandem Diabetes Care, Inc.$711
  • Cequr Corporation$693
  • Corcept Therapeutics$535
  • Amgen$529
  • plus $6K from 34 others

What the payments were for

  • Food & beverage$11,007100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,007 in reported general payments places this provider in the 95th percentile of 8,062 physician assistant providers in Florida.

See all physician assistant providers in Florida

Medicare billing

Part B allowed, 2024
$3,302
Medicare patients
14
Services billed
32

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide271$316,388
MounjaroTirzepatide224$253,445
JardianceEmpagliflozin130$185,258
FarxigaDapagliflozin Propanediol108$120,475
JanuviaSitagliptin Phosphate28$43,246
TrulicityDulaglutide33$38,027
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog32$25,849
VascepaIcosapent Ethyl40$24,461
ProliaDenosumab12$21,052
Synjardy XrEmpagliflozin/Metformin Hcl25$20,339
Fiasp FlextouchInsulin Aspart (Niacinamide)20$19,550
Tresiba Flextouch U-100Insulin Degludec23$19,279
Tresiba Flextouch U-200Insulin Degludec23$17,223
Lantus SolostarInsulin Glargine,hum.Rec.Anlog99$14,248
Humalog Kwikpen U-100Insulin Lispro30$10,641

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,461$316,388271 claims
Lilly USA, LLCMounjaro, Trulicity$1,344$291,472257 claims
Boehringer IngelheimJardiance, Synjardy Xr$150$205,597155 claims
AstraZenecaFarxiga$45$120,475108 claims
AmgenProlia$529$21,05212 claims
AbbVieSynthroid$487$6,05048 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid$475$2,318184 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,062 physician assistant providers in Florida.

Other physician assistant in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →